Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats.
BACKGROUND
Abuse of synthetic cathinones, popularized as "bath salts," has increased dramatically in the USA since their debut in 2010. Preclinical behavioral studies may clarify determinants of the abuse-related effects produced by these compounds.


OBJECTIVE
This study examined behavioral effects of (±)-methcathinone, (±)-3,4-methylenedioxypyrovalerone (MDPV), (±)-3,4-methylenedioxymethcathinone (methylone), and (±)-4-methylmethcathinone (mephedrone) in rats using intracranial self-stimulation (ICSS).


METHODS
Male Sprague-Dawley rats (n = 18) with electrodes targeting the medial forebrain bundle responded for multiple frequencies of brain stimulation and were tested in two phases. First, dose-effect curves for methcathinone (0.1-1.0 mg/kg), MDPV (0.32-3.2 mg/kg), methylone (1.0-10 mg/kg), and mephedrone (1.0-10 mg/kg) were determined. Second, time courses were determined for effects produced by the highest dose of each compound.


RESULTS
Methcathinone produced dose- and time-dependent facilitation of ICSS. MDPV, methylone, and mephedrone produced dose- and time-dependent increases in low rates of ICSS maintained by low brain stimulation frequencies, but also produced abuse-limiting depression of high ICSS rates maintained by high brain stimulation frequencies. Efficacies to facilitate ICSS were methcathinone ≥ MDPV ≥ methylone > mephedrone. Methcathinone was the most potent compound, and MDPV was the longest acting compound.


CONCLUSIONS
All compounds facilitated ICSS at some doses and pretreatment times, which is consistent with abuse liability for each of these compounds. However, efficacies of compounds to facilitate ICSS varied, with methcathinone displaying the highest efficacy and mephedrone displaying the lowest efficacy to facilitate ICSS.
Department of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, PO Box 980613, Richmond, VA, 23298, USA.
J S
JS
Bonano
R A
RA
Glennon
L J
LJ
De Felice
M L
ML
Banks
S S
SS
Negus
D000818:Animals; D052117:Benzodioxoles; D001921:Brain; D003216:Conditioning, Operant / Q000187:drug effects; D003627:Data Interpretation, Statistical; D015198:Designer Drugs / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D007267:Injections; D008297:Male; D008694:Methamphetamine / Q000031:analogs & derivatives*; D011427:Propiophenones; D011759:Pyrrolidines; D051381:Rats; D017207:Rats, Sprague-Dawley; D012646:Self Administration; D012653:Self Stimulation; D019966:Substance-Related Disorders / Q000523:psychology*; D000094982:Synthetic Cathinone
D052117:Benzodioxoles; D015198:Designer Drugs; D011427:Propiophenones; D011759:Pyrrolidines; C047806:monomethylpropion; D008694:Methamphetamine; C548233:mephedrone; C400939:methylone; D000094982:Synthetic Cathinone